Cargando…

Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration. Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC. Design. Obse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Florenzano, Pablo, Guarda, Francisco J., Jaimovich, Rodrigo, Droppelmann, Nicolás, González, Hernán, Domínguez, José M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102728/ https://www.ncbi.nlm.nih.gov/pubmed/27867395 http://dx.doi.org/10.1155/2016/2586512

Ejemplares similares

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019)

Reduction of thyroid radioactive iodine exposure by oral administration of cyclic oligosaccharides
por: Nishi, Kodai, et al.
Publicado: (2023)

Radioactive Iodine Therapy of Differentiated Thyroid Carcinoma: Redesigning the Paradigm
por: Goldsmith, Stanley J.
Publicado: (2017)

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019)

Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea
por: Chung, Jae Hoon
Publicado: (2013)

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
por: McFarland, Daniel C, et al.
Publicado: (2014)

Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of  Differentiated Thyroid Cancer
por: Slonimsky, Einat, et al.
Publicado: (2020)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017)

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
por: Mohamed, Ateesha F., et al.
Publicado: (2015)

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023)

The effect of per os vs subcutaneous (123)iodine administration on percentage thyroidal radioactive iodine uptake in normal cats
por: Cosford, Kevin, et al.
Publicado: (2021)

Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer
por: Fordham, Beth A, et al.
Publicado: (2015)

The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis
por: Lin, Jen-Der, et al.
Publicado: (2018)

ODP532 Fractionated Radioactive Iodine Therapy in Management of Differentiated Thyroid Cancer
por: Khan, Adeel Ahmad, et al.
Publicado: (2022)

Effect of Psychological Intervention on Differentiated Thyroid Cancer Patients in the Treatment with Radioactive Iodine
por: Liu, Yan-Bin, et al.
Publicado: (2023)

Radioactive iodine uptake in hyperthyroid cats after administration of recombinant human thyroid stimulating hormone
por: Oberstadt, Amy E., et al.
Publicado: (2018)

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
por: Fullmer, Tanner, et al.
Publicado: (2021)

Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
por: Riachy, Ruba, et al.
Publicado: (2020)

MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)
por: Leboulleux, Sophie, et al.
Publicado: (2021)

Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma
por: Creach, Kimberly M., et al.
Publicado: (2012)

Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021)

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer
por: An, Jee Hyun, et al.
Publicado: (2016)

Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients
por: Mei, Xiaoran, et al.
Publicado: (2021)

Assessment of Long-Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine
por: Sönmez, Bircan, et al.
Publicado: (2021)

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation
por: Zavala, Luis Felipe, et al.
Publicado: (2019)

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma
por: Murayama, Daisuke, et al.
Publicado: (2021)

Comparison of the Carcinogenic Effect of X-Irradiation with Radioactive Iodine on the Rat's Thyroid
por: Doniach, I.
Publicado: (1957)

Effects of Radioactive Iodine on the Rat Thyroid's Function, Regeneration and Response to Goitrogens
por: Doniach, I., et al.
Publicado: (1955)

Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
por: Kim, Sun Hwa, et al.
Publicado: (2013)

Sarcoidosis mimicking metastatic thyroid cancer following radioactive iodine therapy
por: Myint, Zin W., et al.
Publicado: (2015)

Thyroid Storm and Complete Heart Block after Treatment with Radioactive Iodine
por: Vennard, Kaitlyn, et al.
Publicado: (2018)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

Radioactive Body Burden Measurements in (131)Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body (131)Iodine Clearance
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2014)

Extremity Radioactive Iodine Uptake on Post-therapeutic Whole Body Scan in Patients with Differentiated Thyroid Cancer
por: Wakabayashi, Hiroshi, et al.
Publicado: (2015)

Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer
por: Hu, Tianpeng, et al.
Publicado: (2016)

DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131)
por: Prpić, Marin, et al.
Publicado: (2019)

Analysis of the Correlation between the Radioactive Iodine Activity and Neutrophil-to-Lymphocyte Ratio in Patients with Differentiated Thyroid Cancer
por: Stanciu, Adina Elena, et al.
Publicado: (2022)

The effect of radioactive iodine treatment for differentiated thyroid cancer on male gonadal function: a meta-analysis
por: Cai, Yanling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i1r1tt8cjfopecd99k7m86o2ej